Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, has announced that CEO James Porter, Ph.D., will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 4:00 p.m. ET in Boston. The presentation will focus on Nuvalent's targeted cancer therapies designed to tackle clinically proven kinase targets. A live webcast will be available on their website and archived for 30 days following the conference. The company specializes in innovative treatments for ROS1-positive and ALK-positive non-small cell lung cancer.
- None.
- None.
CAMBRIDGE, Mass., Aug. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022, at 4:00 p.m. ET in Boston.
A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference-301598115.html
SOURCE Nuvalent, Inc.
FAQ
When will Nuvalent present at the Canaccord Genuity Annual Growth Conference?
Who is presenting for Nuvalent at the conference?
What is the focus of Nuvalent's presentation?
How can I watch Nuvalent's presentation?
What types of cancer does Nuvalent specialize in?
